The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity
Open accessAbstract
Transfected siRNAs and miRNAs regulate numerous transcripts that have only limited complementarity to the active strand of the RNA duplex. This process reflects natural target regulation by miRNAs, but is an unintended (“off-target”) consequence of siRNA-mediated silencing. Here we demonstrate that this unintended off-target silencing is widespread, and occurs in a manner reminiscent of target silencing by miRNAs. A high proportion of unintended transcripts silenced by siRNAs showed 3' UTR sequence complementarity to the seed region of the siRNA. Base mismatches within the siRNA seed region reduced the set of original off-target transcripts but generated new sets of silenced transcripts with sequence complementarity to the mismatched seed sequence. An inducible shRNA silenced a subset of transcripts that were silenced by an siRNA of the same sequence, demonstrating that unintended silencing is sequence mediated and is independent of delivery method. In all cases, off-target transcript silencing was accompanied by loss of the corresponding protein and occurred with dependence on siRNA concentration similar to that of silencing of the target transcript. Thus, short stretches of sequence complementarity to the siRNA or shRNA seed region are key to the silencing of unintended transcripts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved tools for biological sequence comparison.
Pearson, W. R., & Lipman, D. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.8.2444 · Cited by 11,227
Prediction of Mammalian MicroRNA Targets
Lewis, B. P., Shih, I.-H., Jones-Rhoades, M. W., Bartel, D. P., & Burge, C. B. (2003) · Cell · doi:10.1016/s0092-8674(03)01018-3 · Cited by 5,199
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
Self-citationCombinatorial microRNA target predictions
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., MacMenamin, P., da Piedade, I., Gunsalus, K. C., Stoffel, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1536 · Cited by 4,603
Wightman, B., Ha, I., & Ruvkun, G. (1993) · Cell · doi:10.1016/0092-8674(93)90530-4 · Cited by 4,292
Principles of MicroRNA–Target Recognition
Brennecke, J., Stark, A., Russell, R. B., & Cohen, S. M. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030085 · Cited by 2,378
Expression profiling reveals off-target gene regulation by RNAi
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370 · cited 11×
“Sequence analysis of several off-target transcripts revealed only partial complementarity with the transfected siRNAs, notably at the 59 end of the siRNA guide strand (Jackson et al. 2003).”
BackgroundMethodResultSelf-citationXie, X., Lu, J., Kulbokas, E. J., Golub, T. R., Mootha, V., Lindblad-Toh, K., Lander, E. S., & Kellis, M. (2005) · Nature · doi:10.1038/nature03441 · Cited by 1,872 · cited 1×
“…by miRNAs (Lewis et al. 2003; Stark et al. 2003; Brennecke et al. 2005; Farh et al. 2005; Grun et al. 2005; Krek et al. 2005; Lim et al. 2005; Xie et al. 2005) Intended and unintended transcript silencing could not be distinguished by reducing the siRNA concentration or time of transfection…”
BackgroundMicroRNA-Directed Cleavage of HOXB8 mRNA
Yekta, S., Shih, I.-H., & Bartel, D. P. (2004) · Science · doi:10.1126/science.1097434 · Cited by 1,702
Specificity of microRNA target selection in translational repression
Doench, J. G., & Sharp, P. A. (2004) · Genes & Development · doi:10.1101/gad.1184404 · Cited by 1,636
Cited by
Predicting effective microRNA target sites in mammalian mRNAs
Agarwal, V., Bell, G. W., Nam, J.-W., & Bartel, D. P. (2015) · eLife · doi:10.7554/elife.05005 · Cited by 7,318
“…3 ′ -UTR isoform quantifications previously generated for HeLa cells ( Nam et al., 2014 ) using poly(A)-position profiling by sequencing (3P-seq) ( Jan et al., 2011 ), and developed our model using the dominant mRNA from the subset of genes for which ≥ 90% of the 3P-seq tags corresponded to a…”
MethodGenome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Defining a Cancer Dependency Map
Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551
Dysregulation of Cardiogenesis, Cardiac Conduction, and Cell Cycle in Mice Lacking miRNA-1-2
Zhao, Y., Ransom, J. F., Li, A., Vedantham, V., von Drehle, M., Muth, A. N., Tsuchihashi, T., McManus, M. T., Schwartz, R. J., & Srivastava, D. (2007) · Cell · doi:10.1016/j.cell.2007.03.030 · Cited by 1,429
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
The current landscape of nucleic acid therapeutics
Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00898-0 · Cited by 1,371
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
Illuminating the silence: understanding the structure and function of small RNAs
Rana, T. M. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2085 · Cited by 1,083
Jackson, A. L., & Linsley, P. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3010 · Cited by 1,083
Self-citationsiRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
Strategies for silencing human disease using RNA interference
Kim, D. H., & Rossi, J. J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2006 · Cited by 1,078
“The siRNA guide strand might function as a miRNA when it contains seed-sequence matches to mRNA 3′ UTR regions, which might lead to harmful OTE”
BackgroundRNAi therapeutics: Principles, prospects and challenges
Aagaard, L., & Rossi, J. J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.005 · Cited by 895
RNA interference in the clinic: challenges and future directions
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., & Sood, A. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2966 · Cited by 820
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 804
Delivery of siRNA Therapeutics: Barriers and Carriers
Wang, J., Lu, Z., Wientjes, M. G., & Au, J. L.-S. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9210-4 · Cited by 798
Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing
Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J. M., Lim, L., Karpilow, J., Nichols, K., et al. (2006) · RNA · doi:10.1261/rna.30706 · Cited by 789
Self-citationCurrent prospects for RNA interference-based therapies
Davidson, B. L., & McCray, P. B. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2968 · Cited by 761
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
Kryukov, G. V., Wilson, F. H., Ruth, J. R., Paulk, J., Tsherniak, A., Marlow, S. E., Vazquez, F., Weir, B. A., Fitzgerald, M. E., Tanaka, M., et al. (2016) · Science · doi:10.1126/science.aad5214 · Cited by 688
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
siRNA vs. shRNA: Similarities and differences
Rao, D. D., Vorhies, J. S., Senzer, N., & Nemunaitis, J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.004 · Cited by 660
Identification and consequences of miRNA–target interactions — beyond repression of gene expression
Hausser, J., & Zavolan, M. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3765 · Cited by 628
Expanding the MicroRNA Targeting Code: Functional Sites with Centered Pairing
Shin, C., Nam, J.-W., Farh, K. K.-H., Chiang, H. R., Shkumatava, A., & Bartel, D. P. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.005 · Cited by 611
Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing
Deleavey, G. F., & Damha, M. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.011 · Cited by 589
Statistical methods for analysis of high-throughput RNA interference screens
Birmingham, A., Selfors, L. M., Forster, T., Wrobel, D., Kennedy, C. J., Shanks, E., Santoyo-Lopez, J., Dunican, D. J., Long, A., Kelleher, D., et al. (2009) · Nature Methods · doi:10.1038/nmeth.1351 · Cited by 586
Transcripts Targeted by the MicroRNA-16 Family Cooperatively Regulate Cell Cycle Progression
Linsley, P. S., Schelter, J., Burchard, J., Kibukawa, M., Martin, M. M., Bartz, S. R., Johnson, J. M., Cummins, J. M., Raymond, C. K., Dai, H., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02005-06 · Cited by 552
Self-citationTargeting circular RNAs as a therapeutic approach: current strategies and challenges
He, A. T., Liu, J., Li, F., & Yang, B. B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00569-5 · Cited by 549
Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs
Khan, A. A., Betel, D., Miller, M. L., Sander, C., Leslie, C. S., & Marks, D. S. (2009) · Nature Biotechnology · doi:10.1038/nbt.1543 · Cited by 534
Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR
Boettcher, M., & McManus, M. T. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.028 · Cited by 516
Targeting long non-coding RNAs in cancers: Progress and prospects
Li, C. H., & Chen, Y. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.030 · Cited by 473
Silencing disease genes in the laboratory and the clinic
Watts, J. K., & Corey, D. R. (2012) · The Journal of Pathology · doi:10.1002/path.2993 · Cited by 470
Nonviral delivery of synthetic siRNAs in vivo
Akhtar, S., & Benter, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33494 · Cited by 464
Lipid-based systemic delivery of siRNA
Tseng, Y.-C., Mozumdar, S., & Huang, L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.003 · Cited by 463
Chemical Modification of siRNAs for In Vivo Use
Behlke, M. A. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0164 · Cited by 454
Editing the epigenome: technologies for programmable transcription and epigenetic modulation
Thakore, P. I., Black, J. B., Hilton, I. B., & Gersbach, C. A. (2016) · Nature Methods · doi:10.1038/nmeth.3733 · Cited by 451
Preclinical and clinical development of siRNA-based therapeutics
Ozcan, G., Ozpolat, B., Coleman, R. L., Sood, A. K., & Lopez-Berestein, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.007 · Cited by 449
Förstemann, K., Horwich, M. D., Wee, L., Tomari, Y., & Zamore, P. D. (2007) · Cell · doi:10.1016/j.cell.2007.05.056 · Cited by 438
Perfect seed pairing is not a generally reliable predictor for miRNA-target interactions
Didiano, D., & Hobert, O. (2006) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1138 · Cited by 435
The growing catalog of small RNAs and their association with distinct Argonaute/Piwi family members
Farazi, T. A., Juranek, S. A., & Tuschl, T. (2008) · Development · doi:10.1242/dev.005629 · Cited by 435
Chemically modified siRNA: tools and applications
Watts, J. K., Deleavey, G. F., & Damha, M. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.05.007 · Cited by 431
siRNA Delivery Strategies: A Comprehensive Review of Recent Developments
Tatiparti, K., Sau, S., Kashaw, S., & Iyer, A. (2017) · Nanomaterials · doi:10.3390/nano7040077 · Cited by 429
Pharmacology of Antisense Drugs
Bennett, C. F., Baker, B. F., Pham, N., Swayze, E., & Geary, R. S. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104846 · Cited by 425
McFarland, J. M., Ho, Z. V., Kugener, G., Dempster, J. M., Montgomery, P. G., Bryan, J. G., Krill-Burger, J. M., Green, T. M., Vazquez, F., Boehm, J. S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06916-5 · Cited by 403
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A.-M., Choi, Y. H., & Tu, M.-J. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 395
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Bajan, S., & Hutvagner, G. (2020) · Cells · doi:10.3390/cells9010137 · Cited by 393
RETRACTED: Secondary siRNAs Result from Unprimed RNA Synthesis and Form a Distinct Class
Sijen, T., Steiner, F. A., Thijssen, K. L., & Plasterk, R. H. A. (2007) · Science · doi:10.1126/science.1136699 · Cited by 383
RetractedDistance constraints between microRNA target sites dictate efficacy and cooperativity
Sætrom, P., Heale, B. S. E., Snøve, O., Aagaard, L., Alluin, J., & Rossi, J. J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm133 · Cited by 375
Finnerty, J. R., Wang, W.-X., Hébert, S. S., Wilfred, B. R., Mao, G., & Nelson, P. T. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.07.051 · Cited by 371
High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy
Hasson, S. A., Kane, L. A., Yamano, K., Huang, C.-H., Sliter, D. A., Buehler, E., Wang, C., Heman-Ackah, S. M., Hessa, T., Guha, R., et al. (2013) · Nature · doi:10.1038/nature12748 · Cited by 365
Ghildiyal, M., Xu, J., Seitz, H., Weng, Z., & Zamore, P. D. (2010) · RNA · doi:10.1261/rna.1972910 · Cited by 362
siRNA Conjugate Delivery Systems
Jeong, J. H., Mok, H., Oh, Y.-K., & Park, T. G. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800278e · Cited by 338
Target mRNA abundance dilutes microRNA and siRNA activity
Arvey, A., Larsson, E., Sander, C., Leslie, C. S., & Marks, D. S. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.24 · Cited by 335
Frazier, K. S. (2015) · Toxicologic Pathology · doi:10.1177/0192623314551840 · Cited by 334
Global Positioning System: Understanding Long Noncoding RNAs through Subcellular Localization
Carlevaro-Fita, J., & Johnson, R. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.02.008 · Cited by 318
Administration, distribution, metabolism and elimination of polymer therapeutics
Markovsky, E., Baabur-Cohen, H., Eldar-Boock, A., Omer, L., Tiram, G., Ferber, S., Ofek, P., Polyak, D., Scomparin, A., & Satchi-Fainaro, R. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.021 · Cited by 313
Zscan4: A novel gene expressed exclusively in late 2-cell embryos and embryonic stem cells
Falco, G., Lee, S.-L., Stanghellini, I., Bassey, U. C., Hamatani, T., & Ko, M. S. H. (2007) · Developmental Biology · doi:10.1016/j.ydbio.2007.05.003 · Cited by 306
Genome-scale RNAi profiling of cell division in human tissue culture cells
Kittler, R., Pelletier, L., Heninger, A.-K., Slabicki, M., Theis, M., Miroslaw, L., Poser, I., Lawo, S., Grabner, H., Kozak, K., et al. (2007) · Nature Cell Biology · doi:10.1038/ncb1659 · Cited by 304
Self-citationOn the art of identifying effective and specific siRNAs
Pei, Y., & Tuschl, T. (2006) · Nature Methods · doi:10.1038/nmeth911 · Cited by 302
Deng, Y., Wang, C. C., Choy, K. W., Du, Q., Chen, J., Wang, Q., Li, L., Chung, T. K. H., & Tang, T. (2014) · Gene · doi:10.1016/j.gene.2013.12.019 · Cited by 301
A status report on RNAi therapeutics
Vaishnaw, A. K., Gollob, J., Gamba-Vitalo, C., Hutabarat, R., Sah, D., Meyers, R., de Fougerolles, T., & Maraganore, J. (2010) · Silence · doi:10.1186/1758-907x-1-14 · Cited by 297
Silencing of HIV-1 with RNA Interference: a Multiple shRNA Approach
ter Brake, O., Konstantinova, P., Ceylan, M., & Berkhout, B. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.07.007 · Cited by 293
siRNA therapeutics: a clinical reality
Saw, P. E., & Song, E.-W. (2020) · Science China Life Sciences · doi:10.1007/s11427-018-9438-y · Cited by 291
Naito, Y., Yoshimura, J., Morishita, S., & Ui-Tei, K. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-392 · Cited by 286
RNAi‐based therapeutics–current status, challenges and prospects
Tiemann, K., & Rossi, J. J. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900023 · Cited by 283
RNAi-based drug design: considerations and future directions
Tang, Q., & Khvorova, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00912-9 · Cited by 282
Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
Janas, M. M., Schlegel, M. K., Harbison, C. E., Yilmaz, V. O., Jiang, Y., Parmar, R., Zlatev, I., Castoreno, A., Xu, H., Shulga-Morskaya, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02989-4 · Cited by 279
Designing siRNA That Distinguish between Genes That Differ by a Single Nucleotide
Schwarz, D. S., Ding, H., Kennington, L., Moore, J. T., Schelter, J., Burchard, J., Linsley, P. S., Aronin, N., Xu, Z., & Zamore, P. D. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020140 · Cited by 271
Self-citationAdvances in siRNA delivery in cancer therapy
Singh, A., Trivedi, P., & Jain, N. K. (2018) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2017.1307210 · Cited by 271
A small molecule enhances RNA interference and promotes microRNA processing
Shan, G., Li, Y., Zhang, J., Li, W., Szulwach, K. E., Duan, R., Faghihi, M. A., Khalil, A. M., Lu, L., Paroo, Z., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1481 · Cited by 263
Heme oxygenase-1 in tumor biology and therapy
Was, H., Dulak, J., & Jozkowicz, A. (2010) · Current Drug Targets · doi:10.2174/1389450111009011551 · Cited by 259
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy
Gulino, A. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s23696 · Cited by 258
Reexamining assumptions about miRNA-guided gene silencing
Kilikevicius, A., Meister, G., & Corey, D. R. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1256 · Cited by 194
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer
Kim, J., McMillan, E., Kim, H. S., Venkateswaran, N., Makkar, G., Rodriguez-Canales, J., Villalobos, P., Neggers, J. E., Mendiratta, S., Wei, S., et al. (2016) · Nature · doi:10.1038/nature19771 · Cited by 202
Chen, P. Y., Weinmann, L., Gaidatzis, D., Pei, Y., Zavolan, M., Tuschl, T., & Meister, G. (2008) · RNA · doi:10.1261/rna.789808 · Cited by 176
McManus, K. J., Barrett, I. J., Nouhi, Y., & Hieter, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813414106 · Cited by 133
RNA Interference (RNAi) Screening in Drosophila
Heigwer, F., Port, F., & Boutros, M. (2018) · Genetics · doi:10.1534/genetics.117.300077 · Cited by 125
Harnessing CRISPR/Cas systems for programmable transcriptional and post-transcriptional regulation
Mahas, A., Neal Stewart, C., & Mahfouz, M. M. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.11.008 · Cited by 110
New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer
Yamato, K., Yamada, T., Kizaki, M., Ui-Tei, K., Natori, Y., Fujino, M., Nishihara, T., Ikeda, Y., Nasu, Y., Saigo, K., et al. (2008) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701118 · Cited by 110
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering
Bramsen, J. B., & Kjems, J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00154 · Cited by 92
“…(Amarzguioui et al., 2003; Chiu and Rana, 2003; Czauderna et al., 2003; Grunweller et al., 2003; Prakash et al., 2005; Choung et al., 2006; Jackson et al., 2006a); 2′-OMe slightly enhances the binding affinity toward RNA (T m increase of 0.5–0.7˚C per modification) and is well-tolerated…”
BackgroundInfluentialNanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs
Huang, W., Chen, L., Kang, L., Jin, M., Sun, P., Xin, X., Gao, Z., & Bae, Y. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.004 · Cited by 77
Smart Nanocarriers for the Delivery of Nucleic Acid‐Based Therapeutics: A Comprehensive Review
Ramasamy, T., Munusamy, S., Ruttala, H. B., & Kim, J. O. (2021) · Biotechnology Journal · doi:10.1002/biot.201900408 · Cited by 76
R2D2 Organizes Small Regulatory RNA Pathways in Drosophila∇†
Okamura, K., Robine, N., Liu, Y., Liu, Q., & Lai, E. C. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01141-10 · Cited by 70
Control of the localization and function of a miRNA silencing component TNRC6A by Argonaute protein
Nishi, K., Takahashi, T., Suzawa, M., Miyakawa, T., Nagasawa, T., Ming, Y., Tanokura, M., & Ui-Tei, K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1026 · Cited by 43
Thermodynamic Control of Small RNA-Mediated Gene Silencing
Ui-Tei, K., Nishi, K., Takahashi, T., & Nagasawa, T. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00101 · Cited by 31
“2′-O-methyl modification of the guide strand seed region alters the RISC conformation and reduces seed-dependent off-target effects by dissociating off-target transcripts with weak binding to the guide strand (Jackson et al., 2006b).”
InfluentialOptimization of specific RNA knockdown in mammalian cells with CRISPR-Cas13
Burris, B. J. D., Molina Vargas, A. M., Park, B. J., & O'Connell, M. R. (2022) · Methods · doi:10.1016/j.ymeth.2022.08.007 · Cited by 13
Metadata
- Authors
- Jackson, A. L., Burchard, J., Schelter, J., Chau, B. N., Cleary, M., Lim, L., & Linsley, P. S.
- Venue
- RNA
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2006-05-08
- Volume
- 12
- Issue
- 7
- Pages
- 1179-1187
- ISSN
- 1355-8382 (ISSN-L)
- 1469-9001
- OpenAlex
- W2165586566
- Cited by
- 956
- References
- 23
- FWCI
- 26.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.